

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

VOLUNTARY ANNOUNCEMENT
REGISTRATION APPROVAL IN NEW ZEALAND
FOR KEN-VALVE AND LUX-VALVE PLUS

This announcement is made by Jenscare Scientific Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business and product development of the Group.

The board of directors (“**Directors**”) of the Company (“**Board**”) is pleased to announce that Ken-Valve, the transcatheter aortic valve replacement system, and LuX-Valve Plus, the transcatheter tricuspid valve replacement system, of the Company have recently obtained registration approval from New Zealand Medicines and Medical Devices Safety Authority, and the Company is actively promoting the commercialization of these two products in New Zealand.

Attributable to the design advantages of the products, the progressing registration clinical trial and the ongoing treatment promotion activities, Ken-Valve and LuX-Valve Plus have gained widespread market recognition. Following the registration approval for these two key products by the New Zealand Medicines and Medical Devices Safety Authority, the Company will accelerate the global commercialization of the product portfolio, thereby further achieving its long-term strategic goals.

Cautionary Statement as required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately market and/or commercialize Ken-Valve and/or LuX-Valve Plus successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Jenscare Scientific Co., Ltd.
Mr. PAN Fei
Executive Director and Chief Executive Officer

Hong Kong, February 26, 2026

As at the date of this announcement, the executive Director of the Company is Mr. PAN Fei; the non-executive Directors are Mr. LV Shiwen, Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.